In addition, a new compound as dual-target inhibitor of PARP and EZH2, synthesized on the basis of olaparib and tazemetostat by linking the two drug molecules through hydrogen bonding, inhibited tumors 15–80 times more effectively than the PARP inhibitor alone in a BRCA wild-type triple-negative breast cancer cell line (Wang et al., 2021). Here, PARP1 is linked to triple-negative breast carcinoma.